JP2018197240A5 - - Google Patents

Download PDF

Info

Publication number
JP2018197240A5
JP2018197240A5 JP2018131875A JP2018131875A JP2018197240A5 JP 2018197240 A5 JP2018197240 A5 JP 2018197240A5 JP 2018131875 A JP2018131875 A JP 2018131875A JP 2018131875 A JP2018131875 A JP 2018131875A JP 2018197240 A5 JP2018197240 A5 JP 2018197240A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral pharmaceutical
composition according
oil
liquid formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018131875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018197240A (ja
Filing date
Publication date
Priority claimed from PCT/IL2013/050007 external-priority patent/WO2013102899A1/en
Application filed filed Critical
Publication of JP2018197240A publication Critical patent/JP2018197240A/ja
Publication of JP2018197240A5 publication Critical patent/JP2018197240A5/ja
Pending legal-status Critical Current

Links

JP2018131875A 2013-01-03 2018-07-11 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 Pending JP2018197240A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ILPCT/IL2013/050007 2013-01-03
PCT/IL2013/050007 WO2013102899A1 (en) 2012-01-03 2013-01-03 Methods and compositions for treating diabetes
US201361763996P 2013-02-13 2013-02-13
US61/763,996 2013-02-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015551250A Division JP2016505613A (ja) 2013-01-03 2014-01-02 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020102461A Division JP2020180126A (ja) 2013-01-03 2020-06-12 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2018197240A JP2018197240A (ja) 2018-12-13
JP2018197240A5 true JP2018197240A5 (enExample) 2019-01-31

Family

ID=51062529

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015551250A Pending JP2016505613A (ja) 2013-01-03 2014-01-02 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2018131875A Pending JP2018197240A (ja) 2013-01-03 2018-07-11 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2020102461A Pending JP2020180126A (ja) 2013-01-03 2020-06-12 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2022156787A Pending JP2023002570A (ja) 2013-01-03 2022-09-29 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2025040577A Pending JP2025106279A (ja) 2013-01-03 2025-03-13 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015551250A Pending JP2016505613A (ja) 2013-01-03 2014-01-02 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020102461A Pending JP2020180126A (ja) 2013-01-03 2020-06-12 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2022156787A Pending JP2023002570A (ja) 2013-01-03 2022-09-29 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2025040577A Pending JP2025106279A (ja) 2013-01-03 2025-03-13 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Country Status (5)

Country Link
US (4) US20150335715A1 (enExample)
EP (2) EP2941267B1 (enExample)
JP (5) JP2016505613A (enExample)
CN (2) CN110151979A (enExample)
WO (1) WO2014106846A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006288703B2 (en) * 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
CA3083198A1 (en) 2008-03-26 2009-10-01 Oramed Ltd. Methods and compositions for oral administration of proteins
EP2300031B1 (en) 2008-05-05 2017-09-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (en) 2012-02-01 2024-04-10 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
WO2014142219A1 (ja) 2013-03-13 2014-09-18 アステラス製薬株式会社 グアニジノ安息香酸エステル化合物
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3197913B1 (en) * 2014-09-22 2019-08-28 Hadasit Medical Research Services And Development Alpha-1 anti-trypsin for treating liver diseases
US10588880B2 (en) 2016-09-28 2020-03-17 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
CN109806386A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Fxr激动剂与glp-1类似物的药物组合物和用途
SG11202012340SA (en) * 2018-06-11 2021-01-28 Oramed Ltd Recombinant protease inhibitor-containing compositions, methods for producing same and uses thereof
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
CN116251192A (zh) * 2020-01-16 2023-06-13 上海仁会生物制药股份有限公司 Glp-1给药方案

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja) 1986-08-20 1988-03-03 株式会社東芝 高速増殖炉の崩壊熱除去システム
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
ES2045276T3 (es) 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
JPH02250823A (ja) 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DE69333025T2 (de) * 1992-11-17 2004-04-29 E.I. Du Pont De Nemours And Co., Wilmington Für mikrosom delta 12 fettsäuredesaturase kodierende gene und verwandte enzyme von pflanzen
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
JPH10330287A (ja) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
CN1245216C (zh) * 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko) 2001-03-08 2001-07-25 서종수 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
KR20010069433A (ko) 2001-03-22 2001-07-25 김윤완 노루궁뎅이버섯을 이용한 건강 보조 식품
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
EP1414474A4 (en) 2001-07-18 2005-06-29 Solae Llc PROTEIN BOWMAN BIRK HEMMER CONCENTRATE AND MANUFACTURING METHOD THEREFOR
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2006097793A2 (en) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
ES2325773T5 (es) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
AU2006288703B2 (en) * 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) 2006-06-30 2011-11-16 北京民海生物科技有限公司 一种包含稳定剂的Exendin-4注射剂药物配方
JP2010508262A (ja) 2006-11-01 2010-03-18 プロノヴァ バイオファーマ ノルゲ アーエス 組成物
EP2144618B2 (en) 2007-03-28 2024-11-20 Aker Biomarine Antarctic As Bioeffective krill oil compositions
CA3083198A1 (en) 2008-03-26 2009-10-01 Oramed Ltd. Methods and compositions for oral administration of proteins
EP2300031B1 (en) * 2008-05-05 2017-09-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009151125A1 (ja) * 2008-06-13 2009-12-17 持田製薬株式会社 肝障害の診断及び治療
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
TWI474835B (zh) * 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
WO2010002418A2 (en) 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
UY32177A (es) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
JP5843755B2 (ja) 2009-05-08 2016-01-13 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸
US20120202849A1 (en) 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
EP2519251A4 (en) 2009-12-30 2013-08-28 Solae Llc ISOLATED CLEANED BOWMAN BIRK PROTEASE HEMMER PROTEINS FROM A SOYA PROCESSING STREAM
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
NZ603319A (en) * 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
CN102970981A (zh) * 2010-07-06 2013-03-13 詹森药业有限公司 糖尿病协同治疗制剂
ES2659763T3 (es) * 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
WO2013010289A1 (zh) 2011-07-15 2013-01-24 Chan Tu Cheng 填充式工件表面饰化方法
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (en) 2012-02-01 2024-04-10 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
EP2844269A4 (en) * 2012-03-28 2016-01-06 Amylin Pharmaceuticals Llc TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES
EP2941267B1 (en) * 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld

Similar Documents

Publication Publication Date Title
JP2016505613A5 (enExample)
JP2012500254A5 (enExample)
Lee et al. Chlorogenic acid ameliorates brain damage and edema by inhibiting matrix metalloproteinase-2 and 9 in a rat model of focal cerebral ischemia
JP2023002662A5 (enExample)
ES2839453T3 (es) Métodos para el tratamiento de enfermedades colestásicas y fibróticas
JP2023002570A (ja) Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
US20120115782A1 (en) Compositions and methods for treating or inhibiting liver injury
JP2018504444A5 (ja) 医薬組成物
RU2013130611A (ru) Способы и композиции для перорального введения белков
JP2018504445A5 (enExample)
HK1247835A1 (zh) 甲状旁腺功能减退症的治疗
RU2010146372A (ru) Композиции и способы перорального введения эксенатида
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
HRP20180425T1 (hr) Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
JP2009530395A5 (enExample)
Zhou et al. Saikosaponin A protects against dextran sulfate sodium-induced colitis in mice
Kumar et al. Novel formulation approaches used for the management of osteoarthritis: a recent review
BR112015019264A8 (pt) cápsulas para o tratamento de helicobacter pylori e seu uso".
JP2020500864A5 (enExample)
CN112245419A (zh) 包括15-hepe的组合物以及使用其治疗或预防纤维化的方法
PH12022551148A1 (en) Injectable compositions of ursodeoxycholic acid
FI3706724T3 (fi) Suun kautta otettavia rifamysiini sv -koostumuksia
HRP20241491T1 (hr) Pripravci i metode za liječenje homocistinurije
CN105997970A (zh) γ-氨基丁酸在制备胃粘膜保护剂中的应用